<code id='584E752247'></code><style id='584E752247'></style>
    • <acronym id='584E752247'></acronym>
      <center id='584E752247'><center id='584E752247'><tfoot id='584E752247'></tfoot></center><abbr id='584E752247'><dir id='584E752247'><tfoot id='584E752247'></tfoot><noframes id='584E752247'>

    • <optgroup id='584E752247'><strike id='584E752247'><sup id='584E752247'></sup></strike><code id='584E752247'></code></optgroup>
        1. <b id='584E752247'><label id='584E752247'><select id='584E752247'><dt id='584E752247'><span id='584E752247'></span></dt></select></label></b><u id='584E752247'></u>
          <i id='584E752247'><strike id='584E752247'><tt id='584E752247'><pre id='584E752247'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:49752

          AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

          AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

          advertisement

          The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          Diagnostic tests are hitting their mathematical limits
          Diagnostic tests are hitting their mathematical limits

          Worriedaboutyourhealth?Youcannowavailyourselfofnoninvasivediagnosticsthatclaimtoscreenforrarebirthde

          read more
          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more

          NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

          0:53AmakeshiftmemorialforO'ShaeSibley,a28-year-oldwhowaskilledwhiledancingtoaBeyoncesong,sitsnearthe